Details

Autor(en) / Beteiligte

• Zangrilli, James, MD
• Mansfield, Lyndon E., MD
• Uryniak, Tom, MS
• O'Brien, Christopher D., MD, PhD

Titel

Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial

Ist Teil von

• Annals of allergy, asthma, & immunology, 2011-09, Vol.107 (3), p.258-265.e2

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2011

Quelle

ScienceDirect

Beschreibungen/Notizen

• Background Few clinical trials in asthma have focused on Hispanic populations. Objective To compare the efficacy and safety of budesonide/formoterol (BUD/FM) with BUD in an ethnically diverse group of Hispanic participants with asthma previously treated with inhaled corticosteroids (ICS). Methods This 12-week, randomized, double-blind, active-controlled study ( NCT00419757 ) was designed to enroll Hispanic participants (self-reported) (≥12 years of age) with moderate to severe asthma requiring medium- to high-dose ICS. After a 2-week run-in period (low-dose BUD pressurized metered-dose inhaler [pMDI] 80 μg × 2 inhalations [160 μg] twice daily), participants with a symptom score greater than 0 (scale: 0–3) on 3 or more of 7 run-in days and forced expiratory volume in 1 second (FEV1 ) 45%–85% predicted were randomized to BUD/FM pMDI 160/4.5 μg × 2 inhalations (320/9 μg) twice daily or BUD pMDI 160 μg × 2 inhalations (320 μg) twice daily. Results Randomized participants ( n = 127 BUD/FM; n = 123 BUD) were predominately Mexican (51%) or Puerto Rican (21%). During low-dose ICS run-in, the mean symptom score was 1.0; however, mean predose FEV1 improved (2.10–2.21 L). During randomized treatment, small, but not statistically significant, improvements favored BUD/FM vs BUD ( am peak expiratory flow [PEF; primary efficacy variable] 25.4 vs 19.9 L/min; pm PEF 20.6 vs 15.8 L/min; predose FEV1 0.16 vs 0.11 L; rescue medication use −0.7 vs −0.6 inhalations/d). Most adverse events were mild or moderate in intensity. Conclusions Improvement in clinically relevant control end points occurred in both BUD/FM and BUD groups; both treatments were well tolerated in this Hispanic asthma population but were not significantly differentiated.